Table 3.
Criteria for decision-making included in the framework articles and related studies* (n = 72), systematic review of national decision-making 2010–2020.
| Category | Criteria | Frameworks including criterion (n = 27) | Studiesa mentioning criterion (n = 45) | ||
|---|---|---|---|---|---|
| % (n) | Total n of articles including at least one criteria of the category | % (n) | Total n of articles including at least one criteria of the category | ||
| Vaccine characteristics | Efficacy/effectiveness | 96 (26) | (n = 27) | 93 (41) | (n = 44) |
| Vaccine safety | 93 (25) | 80 (35) | |||
| Delivery issues | 41 (11) | 66 (29) | |||
| Other characteristics | 37 (10) | 30 (13) | |||
| The importance of the health problem | Burden of disease | 100 (26) | (n = 26) | 95 (40) | (n = 42) |
| Political priority | 31 (8) | 62 (26) | |||
| Costs of disease | 50 (13) | 40 (17) | |||
| Perceptions of importance | 38 (10) | 38 (16) | |||
| Other | 23 (6) | 14 (6) | |||
| Financial/economic issues | Economic evaluation | 96 (25) | (n = 26) | 83 (34) | (n = 41) |
| Incremental costs | 27 (7) | 20 (8) | |||
| Funding sources | 12 (3) | 46 (19) | |||
| Vaccine price | 62 (16) | 51 (21) | |||
| Financial sustainability | 31 (8) | 32 (13) | |||
| Other (including affordability) | 35 (9) | 29 (12) | |||
| Consideration of alternative interventions | Cost-effectiveness of alternatives | 96 (24) | (n = 25) | 100 (35) | (n = 35) |
| Effectiveness of alternatives | 40 (10) | 34 (12) | |||
| Other considerations | 16 (4) | 3 (1) | |||
| Decision-making process | Evidence sources/quality of evidence | 75 (18) | (n = 24) | 61 (23) | (n = 38) |
| Stakeholders involved | 67 (16) | 89 (34) | |||
| Procedures | 42 (10) | 66 (25) | |||
| Cues to action | 14 (4) | 29 (11) | |||
| Impact of vaccination | Impact on health outcomes | 90 (19) | (n = 21) | 93 (28) | (n = 30) |
| Impact on non-health outcomes | 67 (14) | 67 (20) | |||
| Effects of coadministration | 5 (1) | 23 (7) | |||
| Risks of serotype replacement | 19 (4) | 20 (6) | |||
| Other impact | 0 (0) | 3 (1) | |||
| Programmatic considerations | Feasibility | 73 (11) | (n =15) | 50 (13) | (n = 26) |
| Vaccine supply | 47 (7) | 69 (18) | |||
| Acceptability | Acceptability of vaccine | 100 (11) | (n = 11) | 100 (20) | (n = 20) |
| Accessibility, equity and ethics | Accessibility, equity and ethics | 100 (13) | (n = 13) | 100 (15) | (n = 15) |
*
Article type 1, Frameworks and article type 2, Studies that collect or analyze empirical data on vaccine adoption decision-making and examples of vaccine adoption decision-making.
a
Studies include the 31 articles that collected empirical data on decision-making and the 14 examples of vaccine introduction decision-making.